- $7.35bn
- $6.72bn
- $36.13m
Drugmaker Merus slips after share offering launch
Merus NV surges after cancer combo-therapy succeeds in mid-stage trial
Brief: Merus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L Pd-L1+ R/M Hnscc
Brief: Merus NV Based On Co's Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities Expected To Fund Merus' Operations Into 2028
Develop Three Novel Bispecific ADC Programs
Brief: Merus Announces First Patient Dosed In Phase 2 Trial Of Petosemtamab In 3L+ Mcrc
Brief: Merus' Petosemtamab Monotherapy Interim Data Continues To Demonstrate Clinically Meaningful Activity In 2L+ R/M HNSCC
Merus rises after US FDA approves therapy to treat lung, pancreatic cancers
Brief: Merus Announces FDA Approval Of Bizengri® (Zenocutuzumab-Zbco)
US FDA approves Merus' therapy to treat lung, pancreatic cancers (updated)
US FDA approves Merus' therapy to treat lung, pancreatic cancers
Merus gains on US commercialization agreement for cancer therapy
Brief: Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Merus falls as FDA extends review of cancer therapy
US FDA extends review of Merus' gene-targeting cancer therapy (updated)
Brief: Merus Receives FDA Extension Of PDUFA For Zenocutuzumab
US FDA extends review of Merus' gene-targeting cancer therapy
Brief: Merus Announces First Patient Dosed In LiGeR-HN2
Brief: Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC